GPR182 is a lipoprotein receptor for dietary fat absorption.

Summary

Using genetic ablation, ultrastructural imaging, and antibody blockade, the authors identify GPR182 on lymphatic endothelial cells as a receptor that enables chylomicron entry into lacteals. Loss or pharmacologic inhibition of GPR182 impairs intestinal lipid absorption, increases circulating HDL, and prevents or treats diet-induced obesity in mice.

Key Findings

• GPR182 on lymphatic endothelial cells mediates chylomicron transport into lacteals, enabling dietary fat absorption.
• GPR182 knockout mice show impaired lipid absorption, delayed growth, resistance to diet-induced obesity, and increased HDL.
• Transmission electron microscopy revealed failure of chylomicron entry into the lacteal lumen with GPR182 loss.
• Monoclonal antibody blockade of GPR182 prevents and treats diet-induced obesity in mice.

Clinical Implications

Targeting GPR182 may reduce intestinal fat uptake and improve atherogenic lipoprotein profiles; if safety is confirmed, anti-GPR182 biologics could complement existing anti-obesity therapies and benefit patients with hyperlipidemia. Vigilance for effects on fat-soluble nutrient absorption will be essential.

Limitations

• Findings are predominantly from mouse models; human validation of GPR182 function in intestinal lymphatics is pending.
• Safety, long-term metabolic consequences, and impacts on fat-soluble nutrient absorption of chronic GPR182 blockade are unknown.

Future Directions

Validate GPR182-mediated transport in human intestinal tissues; assess pharmacology, safety, and nutrient absorption effects of GPR182 inhibitors in large animals; explore indications beyond obesity (e.g., severe hypertriglyceridemia).